BSE Live
Mar 19, 16:01Prev. Close
381.90
Open Price
380.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 19, 15:55Prev. Close
382.25
Open Price
376.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
366.10 (300)
| Key Financial Ratios of SMS Pharmaceuticals (in Rs. Cr.) | Mar 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 20.14 | 17.62 | |
| Diluted EPS (Rs.) | 20.14 | 17.62 | |
| Cash EPS (Rs.) | 33.88 | 25.28 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 117.20 | 99.34 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 117.20 | 99.34 | |
| Dividend / Share(Rs.) | 2.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 272.08 | 282.62 | |
| PBDIT/Share (Rs.) | 46.76 | 45.67 | |
| PBIT/Share (Rs.) | 38.19 | 38.01 | |
| PBT/Share (Rs.) | 28.72 | 28.10 | |
| Net Profit/Share (Rs.) | 20.14 | 17.62 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 17.18 | 16.15 | |
| PBIT Margin (%) | 14.03 | 13.44 | |
| PBT Margin (%) | 10.55 | 9.94 | |
| Net Profit Margin (%) | 7.40 | 6.23 | |
| Return on Networth / Equity (%) | 17.18 | 17.73 | |
| Return on Capital Employed (%) | 8.33 | 6.98 | |
| Return on Assets (%) | 5.37 | 5.63 | |
| Total Debt/Equity (X) | 1.31 | 1.27 | |
| Asset Turnover Ratio (%) | 72.56 | 90.34 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 1.51 | 2.68 | |
| Quick Ratio (X) | 1.09 | 1.94 | |
| Inventory Turnover Ratio (X) | 4.85 | 6.33 | |
| Dividend Payout Ratio (NP) (%) | 9.93 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 5.90 | 0.00 | |
| Earnings Retention Ratio (%) | 90.07 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 94.10 | 100.00 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | |
| EV/EBITDA (X) | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | |
| Retention Ratios (%) | 90.06 | 100.00 | |
| Price/BV (X) | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth